Reuters logo
BRIEF-Clovis Oncology presents data from phase 2 studies of rucaparib
2016年6月6日 / 下午12点52分 / 1 年前

BRIEF-Clovis Oncology presents data from phase 2 studies of rucaparib

June 6 (Reuters) - Clovis Oncology Inc :

* No treatment-related deaths were reported

* Nineteen patients (9%) discontinued treatment because of an adverse event.

* Using prespecified 14% cutoff, patients in brca(mut)subgroup demonstrated a 73 percent reduction in risk of progression

* Ariel4 confirmatory study is expected to begin during second half of 2016

* Company is exploring rucaparib in other solid tumor types with significant brca and brca-like populations

* Clovis oncology presents data from phase 2 studies of rucaparib in advanced ovarian cancer and pancreatic cancer at 2016 asco annual meeting Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below